

Kelly M Loyet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4183056/publications.pdf>

Version: 2024-02-01

18
papers

1,216
citations

759233

12
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

2231
citing authors

#	ARTICLE	IF	CITATIONS
1	Fab-Nanolipoprotein Conjugate Causes Vitreous Opacity and Cataracts Following a Single Intravitreal Administration in New Zealand White Rabbits. <i>Toxicologic Pathology</i> , 2021, 49, 647-655.	1.8	0
2	Potent Killing of <i>Pseudomonas aeruginosa</i> by an Antibody-Antibiotic Conjugate. <i>MBio</i> , 2021, 12, e0020221.	4.1	17
3	Dramatic activation of an antibody by a single amino acid change in framework. <i>Scientific Reports</i> , 2021, 11, 22365.	3.3	3
4	Nanolipoprotein Particles as a Delivery Platform for Fab Based Therapeutics. <i>Bioconjugate Chemistry</i> , 2020, 31, 1995-2007.	3.6	11
5	Bivalent antibody pliers inhibit β -tryptase by an allosteric mechanism dependent on the IgG hinge. <i>Nature Communications</i> , 2020, 11, 6435.	12.8	18
6	Identification and characterization of an octameric PEG-protein conjugate system for intravitreal long-acting delivery to the back of the eye. <i>PLoS ONE</i> , 2019, 14, e0218613.	2.5	20
7	Influence of Charge, Hydrophobicity, and Size on Vitreous Pharmacokinetics of Large Molecules. <i>Translational Vision Science and Technology</i> , 2019, 8, 1.	2.2	38
8	Hyaluronic Acid- α -Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics. <i>Bioconjugate Chemistry</i> , 2019, 30, 2782-2789.	3.6	12
9	An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma. <i>Cell</i> , 2019, 179, 417-431.e19.	28.9	76
10	In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. <i>Molecular Pharmaceutics</i> , 2019, 16, 86-95.	4.6	6
11	Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye. <i>MAbs</i> , 2017, 9, 1297-1305.	5.2	16
12	Novel antibody- α -antibiotic conjugate eliminates intracellular <i>S. aureus</i> . <i>Nature</i> , 2015, 527, 323-328.	27.8	663
13	A Mechanistic Pharmacokinetic/Pharmacodynamic Model of Factor D Inhibition in Cynomolgus Monkeys by Lampalizumab for the Treatment of Geographic Atrophy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 355, 288-296.	2.5	26
14	Complement Inhibition in Cynomolgus Monkeys by Anti- α -Factor D Antigen-Binding Fragment for the Treatment of an Advanced Form of Dry Age-Related Macular Degeneration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 527-537.	2.5	41
15	Activation of the Alternative Complement Pathway in Vitreous is Controlled by Genetics in Age-Related Macular Degeneration. , 2012, 53, 6628.		68
16	Structural and Functional Analysis of a C3b-specific Antibody That Selectively Inhibits the Alternative Pathway of Complement. <i>Journal of Biological Chemistry</i> , 2009, 284, 10473-10479.	3.4	53
17	Mass Spectrometric Contributions to the Practice of Phosphorylation Site Mapping through 2003. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 235-245.	3.8	99
18	Proteomic Profiling of Surface Proteins on Th1 and Th2 Cells. <i>Journal of Proteome Research</i> , 2005, 4, 400-409.	3.7	49